Floatz logo

Ipilimumab

Refractory Malignant Solid Neoplasm

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

181 Active assets in the Refractory Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Catequentinib
First Affiliated Hospital of Wannan Medical College
Phase 3BB

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →